# Uncovering Anticancer Mechanisms of Spiramycin Derivatives Using Transcriptomic and Metabolomic Analyses

**Authors:** Renyu Yang, Wuxiyar Otkur, Tingze Feng, Yirong Li, Shaojun Pei, Huan Qi, Yaopeng Zhao, Yao Lu, Hailong Piao

PMC · DOI: 10.3390/metabo15100647 · Metabolites · 2025-09-27

## TL;DR

This study reveals how a spiramycin derivative, h-SPM, fights cancer by disrupting lipid metabolism and increasing cell stress.

## Contribution

The novel contribution is uncovering the anticancer mechanism of h-SPM through integrated transcriptomic and metabolomic analyses.

## Key findings

- h-SPM treatment altered lipid metabolism and mitochondrial biogenesis pathways.
- NR1D1 protein levels decreased, and ROS and pro-inflammatory gene expression increased after h-SPM treatment.
- Ceramide accumulation and ROS generation were linked to apoptosis and inflammation in cancer cells.

## Abstract

Background: Carrimycin is a mixture of spiramycin derivatives with antibacterial functions. However, recent studies have shown that it possesses certain anticancer properties. The specific mechanism of the anticancer activity is unknown. Methods: To study the anticancer mechanism of carrimycin, we synthesized a derivative of spiramycin, n-hexyl spiramycin (h-SPM), and used a combination of metabolomics and transcriptomics methods. Capillary electrophoresis–mass spectrometry (CE-MS) was used to detect polar small molecule metabolites, and liquid chromatography–mass spectrometry (LC-MS) was used to detect lipid metabolites in cells. Transcriptomics was used to measure mRNA content in cells. Finally, by processing these data using specific bioinformatics methods, the mechanism underlying anticancer effect of carrimycin was determined. Results: Metabolomics and transcriptomic results showed that lipid metabolism and mitochondrial biogenesis pathways in the cells changed after hSPM treatment, NR1D1 genes and ceramide were enriched from these pathways, implicating the involvement of ROS and pro-inflammatory response. Western blotting verified that the protein levels of NR1D1 decreased after h-SPM treatment, and ROS stating and qPCR demonstrated that ROS levels and the mRNA levels of pro-inflammatory genes were greatly induced by h-SPM. Conclusions: h-SPM reduced the protein level of NR1D1, disrupted metabolic regulation, accumulating ceramide, and the subsequent increased ROS generation promoted apoptosis and pro-inflammatory-like response of cells. Our findings unveiled the anticancer mechanism of a potent anticancer derivative of spiramycin and unveiled its mechanism of action.

## Linked entities

- **Genes:** NR1D1 (nuclear receptor subfamily 1 group D member 1) [NCBI Gene 9572]
- **Chemicals:** spiramycin (PubChem CID 5266), ceramide (PubChem CID 139583739)

## Full-text entities

- **Genes:** NR1D1 (nuclear receptor subfamily 1 group D member 1) [NCBI Gene 9572] {aka EAR1, REVERBA, REVERBalpha, THRA1, THRAL, ear-1}
- **Diseases:** inflammatory (MESH:D007249)
- **Chemicals:** Spiramycin (MESH:D015572), lipid (MESH:D008055), ceramide (MESH:D002518), ROS (-), Carrimycin (MESH:C423662)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12566170/full.md

## Figures

14 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12566170/full.md

## References

42 references — full list in the complete paper: https://tomesphere.com/paper/PMC12566170/full.md

---
Source: https://tomesphere.com/paper/PMC12566170